KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) Debt to Equity (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Debt to Equity for 17 consecutive years, with $0.16 as the latest value for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 11.77% to $0.16 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.16, a 11.77% decrease, with the full-year FY2025 number at $0.16, down 11.77% from a year prior.
  • Debt to Equity was $0.16 for Q4 2025 at Bio-Rad Laboratories, down from $0.18 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.18 in Q4 2024 to a low of $0.0 in Q3 2021.
  • A 5-year average of $0.12 and a median of $0.14 in 2023 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: plummeted 49.95% in 2021, then surged 20241.86% in 2022.
  • Bio-Rad Laboratories' Debt to Equity stood at $0.0 in 2021, then soared by 16113.57% to $0.12 in 2022, then rose by 10.13% to $0.14 in 2023, then skyrocketed by 33.21% to $0.18 in 2024, then decreased by 11.77% to $0.16 in 2025.
  • Per Business Quant, the three most recent readings for BIO's Debt to Equity are $0.16 (Q4 2025), $0.18 (Q3 2025), and $0.17 (Q2 2025).